ATL45 Antibody

Shipped with Ice Packs
In Stock

Description

ATL (Adult T-cell Leukemia) and CD45 Association

  • ATL is an aggressive T-cell malignancy caused by HTLV-1 infection .

  • CD45 is a protein tyrosine phosphatase critical for T-cell receptor signaling. The CD45.1 alloantigen (Ly5.1) is a mouse isoform studied in immunology .

  • While no "ATL45" antibody exists, research on ATL has utilized anti-CD45 antibodies (e.g., clone A20) to study leukocyte subsets in murine models .

Atlastin (ATL) Homologs

  • Atlastins (ATL1/2/3) are GTPases involved in endoplasmic reticulum membrane fusion. Recent structural studies used single-molecule FRET assays to analyze ATL conformational dynamics .

  • No antibodies designated "ATL45" are referenced in this context.

Chloroplast Protein Complexes

  • In Arabidopsis, AtL45 is a subunit of the TGD1,2,3 lipid transfer complex in chloroplasts . Antibodies against AtL45 (e.g., anti-FLAG) have been used to study protein interactions , but these are unrelated to human diseases.

Antibodies in ATL Research

Relevant antibodies used in ATL studies include:

Antibody TargetClone/FormatApplicationKey Findings
CD45.1 (Ly5.1)A20 (Alexa Fluor® 594)Murine hematopoietic cell differentiation Distinguishes CD45.1+ (SJL) vs. CD45.2+ (C57BL/6) strains in transplantation models.
CCR4Humanized monoclonalATL clinical trials Defucosylated anti-CCR4 antibody enhances antibody-dependent cellular cytotoxicity.
HTLV-1 gp46/gp68Polyclonal seraATLV serodiagnosis Detects ATLV envelope glycoproteins in patient sera; no cross-reactivity with normal donors.

Anti-CD45.1 Antibody (Clone A20)

  • Host Species: Mouse (A.SW IgG2a, κ)

  • Immunogen: SJL mouse thymocytes/splenocytes

  • Applications:

    • IHC-F (2.5–10 μg/ml)

    • Flow cytometry (0.25–1 μg/10^6 cells)

  • Specificity: Does not react with CD45.2+ cells .

Anti-ATLV gp46/gp68 Antibodies

  • Sensitivity: 100% in ATL patients and carriers .

  • Limitations: Poor correlation between immunofluorescence (IF) and immunoprecipitation (IP) results .

Key Research Gaps

  • No studies validate an antibody targeting a hypothetical "ATL45" epitope.

  • The term may represent a nomenclature error, potentially conflating:

    • ATL (disease) + CD45 (marker)

    • Atlastin (ATL) + molecular weight (45 kDa)

Recommendations for Further Investigation

  1. Verify the intended target antigen (e.g., HTLV-1 proteins, CD45 isoforms, or plant TGD complex subunits).

  2. Explore repositories like the Developmental Studies Hybridoma Bank (DSHB) for uncharacterized antibodies.

  3. Consider mass spectrometry or phage display for novel antibody discovery.

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
ATL45 antibody; RHA3B antibody; At4g35480 antibody; F15J1.50Probable E3 ubiquitin-protein ligase ATL45 antibody; EC 2.3.2.27 antibody; RING-H2 finger A3b antibody; RING-H2 finger protein ATL45 antibody; RING-H2 zinc finger protein RHA3b antibody; RING-type E3 ubiquitin transferase ATL45 antibody
Target Names
ATL45
Uniprot No.

Target Background

Function
ATL45 is an E3 ubiquitin-protein ligase exhibiting in vitro E3 ubiquitin ligase activity and mediating protein monoubiquitination (Ref. 10). It triggers the monoubiquitination of phosphorylated BIK1 in response to pathogen-associated molecular pattern (PAMP) detection (Ref. 10). ATL45 is likely involved in the early stages of plant defense signaling pathways.
Database Links

KEGG: ath:AT4G35480

STRING: 3702.AT4G35480.1

UniGene: At.23630

Protein Families
RING-type zinc finger family, ATL subfamily
Subcellular Location
Membrane; Single-pass membrane protein.

Q&A

What are ATL-associated antigens (ATLA) and how are antibodies against them detected in research settings?

ATL-associated antigen complex (ATLA) consists primarily of ATL virus (ATLV) polypeptides and their precursors. Researchers can detect anti-ATLA antibodies through multiple complementary methodologies:

  • Immunofluorescence assay (IF): Provides quantitative detection of antibodies binding to ATLA in fixed cells

  • Radioimmunoprecipitation test: Utilizes purified 125I-gp68 (the putative env gene product of ATLV) for specific quantitative detection

  • Polyacrylamide gel electrophoresis (PAGE): Analyzes immunoprecipitates from 35S-cysteine-labeled cells producing ATLV, providing qualitative results on specific antigen recognition

These methodologies offer different sensitivity profiles; importantly, research has demonstrated that sera yielding negative results in one assay may produce positive results in another, necessitating multiple testing approaches for comprehensive analysis .

How do researchers distinguish between antibody profiles in ATL patients versus healthy carriers?

Anti-ATLA antibodies in seropositive subjects are predominantly directed against glycopolypeptides of ATLV. Research methodologies reveal distinct patterns:

  • All sera from ATL patients and healthy carriers precipitate ATLV-specific glycopolypeptides gp68 and gp46 from 35S-labeled materials

  • Core polypeptides (p28, p24, p19, and p15) are precipitated only by sera with IF titers exceeding 80

  • Quantitative assays (IF and radioimmunoprecipitation) can yield negative results with sera from some patients while detecting ATLA antibodies in all healthy ATLV carriers

These findings indicate that antibody reactivity patterns to ATLA antigens do not clearly differentiate between ATL patients at various disease stages and healthy ATLV carriers, presenting a significant challenge for diagnostic applications .

What methodological approaches can researchers employ to study cross-reactivity of anti-ATLA antibodies between human and non-human primates?

Cross-reactivity studies utilize sophisticated techniques that combine immunological methods with microscopy:

  • Indirect immunoperoxidase method: Enables detection at light microscopy level across multiple cell lines

  • Immunoferritin method: Provides high-resolution detection capabilities

  • Comparative cell line analysis: Utilizing human cell lines (e.g., MT-2) carrying HTLV and monkey cell lines (e.g., Si-1, Si-2, Si-3) carrying either HTLV or type C virus isolated from anti-ATLA-positive monkeys

Electron microscopic examination reveals ferritin or peroxidase labeling of virus particles and plasma membranes across these cell lines when exposed to antibody-positive (but not antibody-negative) human and monkey sera . These findings demonstrate the presence of antigenic determinants common to the surface of type C virus particles of both human and monkey origin, providing critical insights for comparative virology research .

What is the mechanism of action for defucosylated anti-CCR4 monoclonal antibody (KW-0761) in ATL treatment research?

KW-0761 represents an advanced approach to targeting ATL through a mechanism distinctly different from conventional antibodies:

  • Enhanced ADCC: The defucosylated Fc region markedly enhances antibody-dependent cellular cytotoxicity through increased binding affinity to Fcγ receptors on effector cells

  • NK cell activation: Defucosylated IgG1 more potently activates natural killer cells compared to non-defucosylated IgG1 during ADCC

  • Target specificity: Targets CC chemokine receptor 4 (CCR4), which is expressed on tumor cells from most patients with ATL

  • No complement activation: Unlike many therapeutic antibodies, KW-0761 cannot mediate complement-dependent cytotoxicity, suggesting a different mechanism for observed infusion reactions

How can researchers evaluate T-cell subset alterations following anti-CCR4 antibody treatment in experimental models?

Research protocols for monitoring T-cell subset alterations include:

Methodology for T-cell subset analysis:

  • Flow cytometric quantification of circulating blood CD4+ CCR4+, CD4+ CD25+ FOXP3+, CD4+ CCR4−, and CD4− CD8+ cells

  • Longitudinal sampling before treatment, during treatment course, and extended follow-up (at least 4 months post-treatment)

  • Comparison with appropriate controls (healthy donor samples)

Key findings researchers should monitor:

  • Significant reduction of CD4+ CCR4+ and CD4+ CD25+ FOXP3+ cells after initial antibody administration

  • Duration of reduction (persisting at least 4 months after treatment completion)

  • Temporary reduction followed by recovery of CD4+ CCR4− and CD4− CD8+ populations

These patterns provide important biomarkers for treatment efficacy and immune reconstitution dynamics in experimental models .

What pharmacokinetic parameters are most critical when evaluating anti-CCR4 antibodies in ATL research models?

When designing research protocols for anti-CCR4 antibodies like KW-0761, researchers should incorporate these key pharmacokinetic parameters:

ParameterMethodologySignificance
Maximum drug concentrationPlasma sampling per strict protocol timingEstablishes peak drug exposure
Trough drug concentrationSampling immediately before subsequent doseEnsures maintained therapeutic levels
Area under the curve (0-7 days)Serial sampling after first and eighth dosesQuantifies total drug exposure over time
Half-life period (t1/2)Extended sampling after final doseDetermines drug persistence and dosing intervals

Research has demonstrated that KW-0761 exhibits a half-life similar to endogenous human IgG1 after multiple administrations, indicating excellent in vivo stability and no detectable anti-drug antibodies, which are favorable characteristics for therapeutic applications .

How should researchers design clinical evaluations of novel anti-ATL antibodies?

Based on successful methodologies with KW-0761, researchers should consider these design elements:

This approach has successfully demonstrated meaningful clinical activity of KW-0761 with an acceptable toxicity profile in relapsed ATL patients .

How do researchers explain differential sensitivity to anti-CCR4 antibody treatment across various disease sites in ATL?

Research has revealed that ATL in blood appears more responsive to anti-CCR4 antibody therapy than disease at other sites, presenting a complex challenge for investigators. Several hypothetical mechanisms warrant investigation:

  • Drug delivery variations: Potential differences in antibody penetration and concentration across tissues

  • Effector cell availability: Variable presence of ADCC effector cells (NK cells, monocytes/macrophages) across disease sites

  • Microenvironmental factors: Local tissue conditions that may enhance or inhibit antibody efficacy

  • Target antigen density: Potential differences in CCR4 expression levels across different anatomical sites

These factors represent important areas for further investigation to optimize therapeutic approaches for comprehensive disease control .

How do researchers distinguish between atypical antibody responses in respiratory diseases versus ATL?

Studies investigating anti-ATLA antibodies in patients with chronic respiratory diseases have revealed complex patterns requiring careful methodological consideration:

  • Among patients with diffuse panbronchiolitis, some develop adult T-cell leukemia with detectable anti-ATLA antibody, while others present with anti-ATLA-like antibody

  • In idiopathic interstitial pneumonia cases, anti-ATLA-like antibody is frequently detected

  • These antibodies are rarely found in patients with bronchial asthma or sarcoidosis

These findings suggest that antibody testing may have diagnostic utility for respiratory conditions frequently associated with lung cancers, but require careful validation and specificity testing to distinguish from true ATL-related antibodies .

What emerging methodologies might enhance detection and characterization of ATL-associated antibodies?

Building on current research foundations, several methodological innovations warrant investigation:

  • Single-cell antibody profiling: To better characterize the heterogeneity of antibody responses at the individual cell level

  • Advanced imaging techniques: Enhanced visualization of antibody-antigen interactions in situ within tissues

  • Multiplexed detection systems: Simultaneous assessment of multiple antibody specificities

  • Machine learning algorithms: For pattern recognition in complex antibody profiles across diverse patient populations

  • Functional antibody characterization: Beyond binding, assessing functional consequences of antibody-antigen interaction

These approaches could potentially address current limitations in distinguishing between antibody profiles of ATL patients at various disease stages and healthy carriers .

What research opportunities exist for developing next-generation therapeutic antibodies against ATL?

Current research with KW-0761 has established proof-of-concept for targeted antibody therapy in ATL, suggesting several promising research directions:

  • Combination therapy approaches: Investigating synergies between antibody therapies and conventional treatments

  • Enhanced antibody engineering: Further modifications to Fc regions or antigen-binding domains to improve efficacy

  • Alternative target identification: Beyond CCR4, identifying other ATL-specific surface markers

  • Bispecific antibody development: Engaging multiple targets simultaneously for enhanced efficacy

  • Antibody-drug conjugates: Combining target specificity with payload delivery capabilities

The clinically meaningful antitumor activity demonstrated by KW-0761 provides strong rationale for continued investigation in ATL and potentially other T-cell neoplasms .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.